Amarillo Biosciences Reaches Enrollment Goal in Australian Influenza Phase 2 Clinical Trial

AMARILLO, TX, Jul 10 (MARKET WIRE) --
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it
has reached full enrollment in a Phase 2 clinical study of the company's
oral interferon product at the University of Western Australia located in
Perth. A total of 200 healthy volunteers meeting all eligibility criteria
have been enrolled to 16 weeks of treatment with oral interferon or
matching placebo.

The double-blind clinical trial being conducted by Dr. Manfred Beilharz
and colleagues is expected to show that lozenges containing a low dose of
interferon-alpha can prevent infection or reduce the severity of infection
with influenza and other common respiratory viruses when taken once a day
during a typical winter cold/flu season. Final study results are expected
to be available before the end of the year.

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in
global partnership with the Hayashibara Group, which also holds 7% of
Amarillo Biosciences shares and has provided over $18 million in loans,
grants and equity investments. The Company's primary focus is extensive
and ongoing R&D into the use of low-dose, orally administered interferon
as a treatment for a variety of conditions, including influenza,
hepatitis C, chronic cough, and opportunistic infections in patients who
are HIV positive. In its 25-year history, the Company has invested nearly
$40 million to establish oral interferon as a therapeutic agent. The
majority of those funds were invested in clinical trials in an effort to
achieve FDA approval for interferon. Additional information is available
on the web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon or the Company's other product
candidates and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission. In particular, see
"Item 1. Description of Business" and "Item 7A. Qualitative and
Quantitative Disclosures About Market Risk" of the Company's Form 10-K for
the fiscal year ended December 31, 2008.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: p.niemetz@panconsultants.com
Tel: 800-477-7570; 212-344-6464
Fax: 212-618-1276

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: jcummins@amarbio.com
Tel: 806-376-1741 x 13
Fax: 806-376-9301

Copyright 2009, Market Wire, All rights reserved.

-0-